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Abstract: Epidemiologic studies often rely on drug dispensation records to measure   medication 
intake. We aimed to estimate correspondence between general practitioner (GP)-reported   treatment 
and timing of prescription dispensation. From seven GPs in northern Denmark, we obtained 
317 prescription records for 286 patients treated with ten commonly prescribed   medication 
types for chronic diseases. We linked the GP-reported information to the regional   prescription 
database to retrieve patients’ prescription records both prospectively and   retrospectively in 
relation to the GP-reported date of treatment (index date, August 20, 2008 for all patients). 
We computed overall and medication-specific correspondence between GP-reported treatment 
and the timing of dispensation. We computed correspondence based on both exact medication 
and therapeutic subgroup agreement. The correspondence for dispensation within ±90 days 
of GP-reported treatment was 0.81 (95% confidence interval = 0.76–0.85) with variation by 
medication type, ranging from 0.55 for ACE-inhibitors to 1.00 for oral glucose-lowering agents. 
The correspondence was greater when analyzed within therapeutic groups than when analyzed 
for exact medications within these groups.
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Introduction
Pharmacoepidemiology studies often rely on drug dispensation records in prescription 
registries to measure medication intake.1,2 Despite many advantages (eg, large size 
and unselected sample),3 registry data merely approximate the true medication intake, 
reflecting neither its fact nor the timing.1,4 This limitation necessitates an assumption 
of good correspondence between dispensation record and drug intake.4 If untenable, 
such assumption may introduce misclassification of the true drug intake, potentially 
producing misleading results.4
Nevertheless, dispensation data are considered superior to most other measures of 
drug intake, and validation studies commonly use them as a gold standard to assess 
data quality on medication intake reported by patients5,6 or their proxies.7 However, 
little is known about the correspondence between the actual treatment and the timing of 
dispensation. We therefore examined the correspondence between general practitioner 
(GP)-reported treatment with prescription medication and the timing of dispensation, 
using a prescription registry in Denmark.
Materials and methods
Denmark is a welfare state, with universal tax-funded health care.8 GPs are gatekeepers to 
patients’ health care utilization, by providing referrals to hospitals and specialists and by 
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prescribing medicine.8 The primary care sector is responsible 
for most of the outpatient prescribing in Denmark, account-
ing for 96% of the total volume of sold medicinal products in 
2009.9 Prescriptions dispensed in outpatient pharmacies are 
recorded in prescription registries, with information on date 
of dispensation and Anatomical Therapeutic Chemical (ATC) 
classification code of the medicine.10
We obtained data on treatment with reimbursed 
prescription medications from seven general practices in 
the North Jutland region. On a randomly selected calen-
dar date (August 20, 2008, the index date), each GP was 
asked to search his or her electronic records to randomly 
identify up to five patients for each of the ten agents on a 
pre-determined list of prescription medications, commonly 
used to treat chronic diseases:9 proton pump inhibitors; oral 
glucose-lowering drugs; acetylsalicylic acid; diuretics; ACE 
inhibitors; statins; systemic glucocorticoids; nonsteroidal 
anti-inflammatory drugs (NSAIDs); bisphosphonates; and 
adrenergic inhalants. Each reported medication corresponded 
to one prescription record, so that patients using two agents 
of interest contributed two prescription records to the analy-
sis. The GP report of medication intake was considered to 
represent the actual treatment with a given medication on the 
index date. Associated ATC codes are presented in the Tables. 
Via the unique personal identifier, used in all official records 
in Denmark,11 we linked the GP-reported treatment data to 
the patients’ records in the Aarhus University Prescription 
Database, which is a regularly-updated research copy of 
regional prescription records, maintained at our academic 
department.10
We estimated the correspondence between GP report 
and dispensation record as the proportion of GP-provided 
prescription records with a corresponding record in the 
pr  escription database for the same patient. We computed cor-
respondence based on (1) full ATC code agreement, that is, 
correspondence of the entire ATC code, and (2) therapeutic 
subgroup agreement, defined as correspondence of the first 
three ATC code positions (eg, A02). We estimated the cumu-
lative correspondence for 30, 90, 180, 270, and 365 days 
before the index date; 30, 90, and 180 days after the index 
date; ±30 days; and ±90 days. Furthermore, we computed 
the median and interquartile range of retrospective and pro-
spective time intervals between index date and dispensation 
date. All analyses were performed overall and for categories 
of medications listed above. Finally, we stratified the results 
by patient age and gender.
During  the  month  leading  up  to  the  index  date 
(July 20–August 19, 2008), using open-ended questions 
(presented in the Appendix), the study nurse interviewed all 
patients identified from one GP practice; this was done to esti-
mate patient-reported adherence to the prescribed treatment.
Results
Each GP supplied 39 to 50 prescription records, for a total of 
317 prescription records written for 286 patients. Median age of 
the patients was 63 years (range, 12–93) and 51% were men.
Overall, correspondence based on full ATC code agree-
ment was 0.46 (95% confidence interval [CI] = 0.41–0.52) 
for dispensation within 30 days before the index date; 
0.36 (95% CI = 0.30–0.41) for 30 days after the index 
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Table  1  Correspondence  and  95%  confidence  intervals  of  general  practitioner-reported  treatment  and  timing  of  prescription 
dispensation according to time relative to index datea: full agreement and therapeutic group correspondenceb
Correspondence of treatment Days relative to the index date
N ±30 ±90 -365 -270 -180 -90 -30 +30 +90 +180
Full ATC agreement 0.66 (0.60–0.71) 0.81 (0.76–0.85) 0.84 (0.79–0.88) 0.83 (0.78–0.87) 0.81 (0.76–0.85) 0.73 (0.68–0.78) 0.46 (0.41–0.52) 0.36 (0.30–0.41) 0.63 (0.57–0.68) 0.73 (0.68–0.78)
Therapeutic group agreement 0.78 (0.73–0.82) 0.95 (0.92–0.97) 0.97 (0.94–0.98) 0.96 (0.93–0.98) 0.93 (0.90–0.96) 0.85 (0.81–0.89) 0.55 (0.49–0.60) 0.46 (0.41–0.52) 0.77 (0.72–0.81) 0.88 (0.84–0.91)
Correspondence of treatment (full ATC correspondence) by therapeutic subgroup
A02BC proton pump inhibitors 34 0.71 (0.53–0.85) 0.82 (0.65–0.93) 0.82 (0.65–0.93) 0.82 (0.65–0.93) 0.82 (0.65–0.93) 0.71 (0.53–0.85) 0.41 (0.25–0.59) 0.44 (0.27–0.62) 0.68 (0.49–0.83) 0.71 (0.53–0.85)
A10B oral glucose-lowering drugs 34 0.94 (0.80–0.99) 1.00 1.00 1.00 1.00 0.97 (0.85–1.00) 0.74 (0.56–0.87) 0.56 (0.38–0.73) 0.91 (0.76–0.98) 0.94 (0.80–0.99)
B01AC06 acetylsalicylic acid 30 0.67 (0.47–0.83) 0.93 (0.78–0.99) 0.97 (0.83–1.00) 0.97 (0.83–1.00) 0.93 (0.78–0.99) 0.83 (0.65–0.94) 0.43 (0.25–0.63) 0.30 (0.15–0.49) 0.63 (0.44–0.80) 0.87 (0.69–0.96)
C03 diuretics 33 0.64 (0.45–0.80) 0.88 (0.72–0.97) 0.88 (0.72–0.97) 0.79 (0.61–0.91) 0.73 (0.54–0.87) 0.73 (0.54–0.87) 0.27 (0.13–0.46) 0.39 (0.23–0.58) 0.73 (0.54–0.87) 0.85 (0.68–0.95)
C09A ACE inhibitors, plain 31 0.45 (0.27–0.64) 0.55 (0.36–0.73) 0.65 (0.45–0.81) 0.61 (0.42–0.78) 0.61 (0.42–0.78) 0.52 (0.33–0.70) 0.39 (0.22–0.58) 0.10 (0.02–0.26) 0.35 (0.19–0.55) 0.55 (0.36–0.73)
C10AA statins 33 0.73 (0.54–0.87) 0.97 (0.84–1.00) 0.97 (0.84–1.00) 0.97 (0.84–1.00) 0.97 (0.84–1.00) 0.91 (0.76–0.98) 0.58 (0.39–0.75) 0.30 (0.16–0.49) 0.64 (0.45–0.80) 0.85 (0.68–0.95)
H02AB systemic glucocorticoids 25 0.40 (0.21–0.61) 0.56 (0.35–0.76) 0.64 (0.43–0.82) 0.64 (0.43–0.82) 0.64 (0.43–0.82) 0.52 (0.31–0.72) 0.32 (0.15–0.54) 0.20 (0.07–0.41) 0.36 (0.18–0.57) 0.48 (0.28–0.69)
M01A nonsteroidal anti-inflammatory drugs 35 0.86 (0.70–0.95) 0.86 (0.70–0.95) 0.86 (0.70–0.95) 0.86 (0.70–0.95) 0.83 (0.66–0.93) 0.66 (0.48–0.81) 0.54 (0.37–0.71) 0.60 (0.42–0.76) 0.66 (0.48–0.81) 0.69 (0.51–0.83)
M05B bisphosphonates 29 0.45 (0.26–0.64) 0.76 (0.56–0.90) 0.83 (0.64–0.94) 0.83 (0.64–0.94) 0.79 (0.60–0.92) 0.76 (0.56–0.90) 0.45 (0.26–0.64) 0.14 (0.04–0.32) 0.69 (0.49–0.85) 0.69 (0.49–0.85)
r03A adrenergics, inhalants 33 0.61 (0.42–0.77) 0.70 (0.51–0.84) 0.73 (0.54–0.87) 0.73 (0.54–0.87) 0.73 (0.54–0.87) 0.64 (0.45–0.80) 0.45 (0.28–0.64) 0.42 (0.25–0.61) 0.55 (0.36–0.72) 0.61 (0.42–0.77)
Notes: aThe index date is a randomly selected calendar date (August 20, 2008) on which the general practitioners searched their electronic records for patients treated with 
the listed agents. bFull correspondence is defined as full correspondence of the drug’s Anatomical Therapeutic Chemical (ATC) code; therapeutic group agreement is defined 
as correspondence of at least first three positions of the ATC code.
Abbreviation: ACE, angiotensin converting enzyme.Clinical Epidemiology 2012:4
date; 0.66 (95% CI = 0.60–0.71) for ±30 days, and 0.81 
(95% CI = 0.76–0.85) for ±90 days (Table 1). In the period 
preceding the index date, correspondence rose to 0.81 at 
180-days and increased only slightly from then until one year 
before the index date. Correspondence varied by medication 
and achieved 1.00 (100% agreement) only for oral glucose-
lowering agents, within ±90 days relative to the index date 
and within 180 days before the index date. For remaining 
categories, the maximum correspondence achieved during 
the observation time ranged from 0.64 for systemic gluco-
corticoids to 0.97 for acetylsalicylic acid and statins within 
180 to 365 days before the index date. Within ±90 days, 
correspondence ranged from 0.55 for ACE-inhibitors to 1.00 
for oral glucose-lowering agents.
The correspondence was greater when computed based on 
therapeutic subgroup of the ATC code (data not shown). Under 
this definition, within ±90 days of the index date   correspondence 
reached a value of 1.00 for proton pump in  hibitors, ACE-
inhibitors, statins, and systemic gl  ucocorticoids, and exceeded 
0.90 for all remaining m  edications, except for bisphospho-
nates (correspondence = 0.83).
Median time between the index date and dispensation 
retrospectively and prospectively was 24 days and 33 days, 
respectively (Table 2). Median time ranged from 12 days for 
NSAIDs to 55 days for diuretics retrospectively and from 
7.5 days for NSAIDs to 72 days for systemic glucocorticoids 
prospectively.
 The retrospective and prospective time interval between 
index date and dispensation date was shorter for women 
than for men, with variations according to medication 
category (Table A1). There was no material difference in 
correspondence according to patient age.
Of the 40 patients who were interviewed about their drug 
intake, 78.0% (95% CI = 62.0%–89.2%) confirmed taking 
prescription medication reported by their GP.
Discussion
To our knowledge, the present study is the first to examine 
the time dependence of correspondence between GP-reported 
treatment and dispensation for a wide range of medications. 
Dispensations registered in the prescription database before 
the GP report corresponded better with that report than pre-
scriptions registered subsequently, for the time window of the 
same size. The correspondence was greater for therapeutic 
groups than for specific drugs within these groups, suggest-
ing that physicians sometimes misreported the specific drug 
prescribed to their patients, but less often misreported the 
intended therapeutic target. Alternatively, another physician 
may have prescribed a different medication within the same 
therapeutic group (eg, during a hospital admission).
The correspondence of GP-reported treatment varied 
according to the type of medication. Not surprisingly, 
analgesics (NSAIDs) and medications that prevent life-
threatening conditions, such as oral glucose-lowering 
agents, showed shorter median time to dispensation and 
higher correspondence within shorter time span, than other 
medications. Absence of full correspondence between 
GP-reported treatments and dispensation records in the 
prescription database may be explained by non-adherence, 
discontinuation elected by the patient, or use of extra-regional 
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Table  1  Correspondence  and  95%  confidence  intervals  of  general  practitioner-reported  treatment  and  timing  of  prescription 
dispensation according to time relative to index datea: full agreement and therapeutic group correspondenceb
Correspondence of treatment Days relative to the index date
N ±30 ±90 -365 -270 -180 -90 -30 +30 +90 +180
Full ATC agreement 0.66 (0.60–0.71) 0.81 (0.76–0.85) 0.84 (0.79–0.88) 0.83 (0.78–0.87) 0.81 (0.76–0.85) 0.73 (0.68–0.78) 0.46 (0.41–0.52) 0.36 (0.30–0.41) 0.63 (0.57–0.68) 0.73 (0.68–0.78)
Therapeutic group agreement 0.78 (0.73–0.82) 0.95 (0.92–0.97) 0.97 (0.94–0.98) 0.96 (0.93–0.98) 0.93 (0.90–0.96) 0.85 (0.81–0.89) 0.55 (0.49–0.60) 0.46 (0.41–0.52) 0.77 (0.72–0.81) 0.88 (0.84–0.91)
Correspondence of treatment (full ATC correspondence) by therapeutic subgroup
A02BC proton pump inhibitors 34 0.71 (0.53–0.85) 0.82 (0.65–0.93) 0.82 (0.65–0.93) 0.82 (0.65–0.93) 0.82 (0.65–0.93) 0.71 (0.53–0.85) 0.41 (0.25–0.59) 0.44 (0.27–0.62) 0.68 (0.49–0.83) 0.71 (0.53–0.85)
A10B oral glucose-lowering drugs 34 0.94 (0.80–0.99) 1.00 1.00 1.00 1.00 0.97 (0.85–1.00) 0.74 (0.56–0.87) 0.56 (0.38–0.73) 0.91 (0.76–0.98) 0.94 (0.80–0.99)
B01AC06 acetylsalicylic acid 30 0.67 (0.47–0.83) 0.93 (0.78–0.99) 0.97 (0.83–1.00) 0.97 (0.83–1.00) 0.93 (0.78–0.99) 0.83 (0.65–0.94) 0.43 (0.25–0.63) 0.30 (0.15–0.49) 0.63 (0.44–0.80) 0.87 (0.69–0.96)
C03 diuretics 33 0.64 (0.45–0.80) 0.88 (0.72–0.97) 0.88 (0.72–0.97) 0.79 (0.61–0.91) 0.73 (0.54–0.87) 0.73 (0.54–0.87) 0.27 (0.13–0.46) 0.39 (0.23–0.58) 0.73 (0.54–0.87) 0.85 (0.68–0.95)
C09A ACE inhibitors, plain 31 0.45 (0.27–0.64) 0.55 (0.36–0.73) 0.65 (0.45–0.81) 0.61 (0.42–0.78) 0.61 (0.42–0.78) 0.52 (0.33–0.70) 0.39 (0.22–0.58) 0.10 (0.02–0.26) 0.35 (0.19–0.55) 0.55 (0.36–0.73)
C10AA statins 33 0.73 (0.54–0.87) 0.97 (0.84–1.00) 0.97 (0.84–1.00) 0.97 (0.84–1.00) 0.97 (0.84–1.00) 0.91 (0.76–0.98) 0.58 (0.39–0.75) 0.30 (0.16–0.49) 0.64 (0.45–0.80) 0.85 (0.68–0.95)
H02AB systemic glucocorticoids 25 0.40 (0.21–0.61) 0.56 (0.35–0.76) 0.64 (0.43–0.82) 0.64 (0.43–0.82) 0.64 (0.43–0.82) 0.52 (0.31–0.72) 0.32 (0.15–0.54) 0.20 (0.07–0.41) 0.36 (0.18–0.57) 0.48 (0.28–0.69)
M01A nonsteroidal anti-inflammatory drugs 35 0.86 (0.70–0.95) 0.86 (0.70–0.95) 0.86 (0.70–0.95) 0.86 (0.70–0.95) 0.83 (0.66–0.93) 0.66 (0.48–0.81) 0.54 (0.37–0.71) 0.60 (0.42–0.76) 0.66 (0.48–0.81) 0.69 (0.51–0.83)
M05B bisphosphonates 29 0.45 (0.26–0.64) 0.76 (0.56–0.90) 0.83 (0.64–0.94) 0.83 (0.64–0.94) 0.79 (0.60–0.92) 0.76 (0.56–0.90) 0.45 (0.26–0.64) 0.14 (0.04–0.32) 0.69 (0.49–0.85) 0.69 (0.49–0.85)
r03A adrenergics, inhalants 33 0.61 (0.42–0.77) 0.70 (0.51–0.84) 0.73 (0.54–0.87) 0.73 (0.54–0.87) 0.73 (0.54–0.87) 0.64 (0.45–0.80) 0.45 (0.28–0.64) 0.42 (0.25–0.61) 0.55 (0.36–0.72) 0.61 (0.42–0.77)
Notes: aThe index date is a randomly selected calendar date (August 20, 2008) on which the general practitioners searched their electronic records for patients treated with 
the listed agents. bFull correspondence is defined as full correspondence of the drug’s Anatomical Therapeutic Chemical (ATC) code; therapeutic group agreement is defined 
as correspondence of at least first three positions of the ATC code.
Abbreviation: ACE, angiotensin converting enzyme.Clinical Epidemiology 2012:4
or hospital-based pharmacies. Furthermore, low short-term 
correspondence may result from a certain proportion of 
patients having a supply remaining from their last refill, close 
in time to the index date.
For the medications under study, correspondence between 
patients’ self-report in the month before the index date was 
similar to the ±90-day agreement. Lack of full correspon-
dence between GP and patient report may be related not 
only to non-adherence, but also to recall bias and the usual 
variation in medication supply until the next refill on the 
date of the interview.
Studies similar to the present one are uncommon. In New 
Zealand, with health care and reimbursement schemes similar 
to those in Denmark, correspondence between dispensation 
and electronic prescribing records from a general practice 
was 0.97 for simvastatin; 0.98 for metoprolol; 0.95 for ben-
drofluazide; 0.97 for cilazapril; 1.00 for felodipine; and 0.98 
for metformin. With the exception of cilazapril, these results 
are similar to our ±90 day estimates for the corresponding 
therapeutic subgroups (we did not include felodipine and 
metoprolol).12 A Dutch study found only 65% agreement 
between prescription and dispensation records, possibly 
attributable to imperfect individual linkage.13
It is reasonable to assume that correspondence, measured 
in this study, correlates well with adherence. The correspon-
dence between patient and GP report as well as between GP 
report and dispensation in our study indicate satisfactory 
overall levels of adherence (.80%) within 3 months of 
the reported true treatment instance.12,14 Most medications 
examined in this study have a 90-day refill cycle in Denmark. 
If the refill period was 30 days, the overall ±30 day corre-
spondence of 78% likewise indicates reasonable adherence. 
In Sweden, refill adherence was 57% overall, with variation 
by medication type and prescriber type (higher for GPs than 
for specialists).14 Contrary to that study, however, prescription 
issue date in our study was unknown.
Our study has several limitations. First, the sample size 
was relatively small, limiting our ability to obtain meaningful 
subgroup analysis. Second, despite the fact that we selected 
patients randomly, we cannot rule out selection bias. Third, 
because GP records in Denmark allow no search for medica-
tion non-users, we were unable to compute negative predic-
tive values of the treatment absence against the dispensation 
record. Fourth, the estimates of correspondence provided 
here are applicable to outpatient prescriptions for reimbursed 
medications taken regularly. Correspondence may be lower 
for over-the-counter or non-reimbursed medications or for 
medications prescribed for acute or intermittent conditions 
such as those with instructions to take ‘as needed’.15 Finally, 
both the GP-reported treatment and the dispensation records 
are approximations to the actual intake and its timing, since 
it is possible that patients filled prescriptions but never took 
the drug.
Conclusion
The correspondence between GP-reported treatment with 
prescription medicine and dispensation record differs by 
medication type. Correspondence is greater for therapeutic 
group than for specific drugs within therapeutic groups, 
possibly reflecting situations in which physicians misre-
ported the specific prescription, but accurately reported the 
therapeutic target.
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Appendix
Questionnaire used by the study nurse
The questions regard your use of medicine, both on prescrip-
tion and over-the counter.
1.  Have you used any drugs within the previous week?
No  Proceed to next question.
Yes  What  was  the  name(s)  of  the  drug(s)? 
  __________________
Why did you take the drug? __________________
Do you remember the dose? __________________
2.  If you answered no to the previous question:
Have you used any drugs within the previous month?
No  Proceed to next question.
Yes  What  was  the  name(s)  of  the  drug(s)? 
  __________________
Why did you take the drug? __________________
Do you remember the dose? __________________
3.  Have you used any drugs within the previous three 
months?
No  Proceed to next question.
Yes  What  was  the  name(s)  of  the  drug(s)? 
  __________________
Why did you take the drug? __________________
Do you remember the dose? __________________
Thank you for participating.
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Table A1 Median and interquartile range of time (days) elapsed until dispensation of medication relative to the index datea, by gender
Therapeutic subgroup ATC-codeb Retrospective Prospective
Women Men Women Men
Proton pump inhibitors A02BC 22 (12–85) 52 (8.0–71) 17 (7.0–41) 35 (1.0–74)
Oral glucose-lowering drugs A10B 18 (13–46) 16 (7.0–39) 20 (13–33) 30 (13–35)
Acetylsalicylic acid B01AC06 11 (4.0–48) 54.5 (7.0–79) 75 (2.0–78) 51 (26–103)
Diuretics C03 51 (7.0–78) 63 (13–86) 28 (13–76) 54 (19–90)
ACE inhibitors, plain C09A 9 (5.0–15) 25 (12–148) 91 (54–99) 39 (27–89)
Statins C10AA 12 (6.0–28) 46 (9.0–55) 86 (15–100) 57 (6.0–64)
Systemic glucocorticoids H02AB 54 (9.0–61) 30 (5.0–123) 48 (15–76) 72 (14–92)
Nonsteroidal anti-inflammatory drugs M01A 43 (0.0–93) 9 (5.0–26) 7.5 (0.0–19) 7.5 (0.0–26)
Bisphosphonates M05BA 26 (13–55) 50 (50–60) 53 (28–68) 50 (40–58)
Adrenergics, inhalants r03A 23 (6.0–55) 16 (8.0–34) 24 (18–35) 28 (9.0–45)
Overall All above 21 (7.5–62) 28 (8.0–71) 26 (9.0–68) 36 (15–72)
Notes: aThe index date is a randomly selected calendar date (August 20, 2008) on which the general practitioners searched their electronic records for patients treated with 
the listed agents. bAnatomical Therapeutic Chemical (ATC) classification code
Abbreviations: ACE, angiotensin converting enzyme.